share_log

HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $42

Benzinga ·  Aug 11, 2023 06:26

HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and lowers the price target from $50 to $42.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment